Top Markets
Coin of the day
GeneThera, Inc. GeneThera, Inc.

GeneThera, Inc.

GTHR
Rank in Stocks #42192
GeneThera, Inc. is a biotechnology firm dedicated to crafting advanced... GeneThera, Inc. is a biotechnology firm dedicated to crafting advanced diagnostic tools and therapeutic solutions for diseases that can transfer from animals to humans (zoonotic diseases). The company's portfolio includes treatments for a variety of these conditions, such as COVID-19, and illnesses like paratuberculosis (Johne's disease), currently in its Stage III clinical phase, as well as mad cow and chronic wasting diseases, and common bacterial infections like E.coli and salmonella. Furthermore, GeneThera is developing a vaccine specifically targeting Mycobacterium avium subspecies paratuberculosis bacteria. Utilizing its innovative Molecular Robotic/AI Platform and a strategic therapeutic framework, the company strives to inhibit the spread of animal-borne diseases and improve control over zoonotic infectious agents. GeneThera, Inc. operates out of Westminster, Colorado.
Share Price
$0.0001
Last synced: 2025-03-10
Market Cap
$3.53K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade GeneThera, Inc. (GTHR)

Category

P/S ratio for GeneThera, Inc. (GTHR)
P/S ratio as of 2026 TTM: 0
According to GeneThera, Inc. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2026 the company had a P/S ratio of 0.
P/S ratio history for GeneThera, Inc. from 2026 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
Not enough data for the provided dates.
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
9.88 -
US
10.30 -
NL
- -
CH
4.98 -
BE
- -
KR